JPWO2022231978A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022231978A5 JPWO2022231978A5 JP2023565628A JP2023565628A JPWO2022231978A5 JP WO2022231978 A5 JPWO2022231978 A5 JP WO2022231978A5 JP 2023565628 A JP2023565628 A JP 2023565628A JP 2023565628 A JP2023565628 A JP 2023565628A JP WO2022231978 A5 JPWO2022231978 A5 JP WO2022231978A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- pharmaceutical formulation
- seq
- antibody pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179879P | 2021-04-26 | 2021-04-26 | |
| US63/179,879 | 2021-04-26 | ||
| PCT/US2022/026005 WO2022231978A1 (en) | 2021-04-26 | 2022-04-22 | Anti-gal3 antibody formulations and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515968A JP2024515968A (ja) | 2024-04-11 |
| JPWO2022231978A5 true JPWO2022231978A5 (https=) | 2025-04-28 |
| JP2024515968A5 JP2024515968A5 (https=) | 2025-04-28 |
Family
ID=83848624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565628A Pending JP2024515968A (ja) | 2021-04-26 | 2022-04-22 | 抗ｇａｌ３抗体製剤およびその使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240158512A1 (https=) |
| EP (1) | EP4329804A4 (https=) |
| JP (1) | JP2024515968A (https=) |
| CN (1) | CN117561080A (https=) |
| WO (1) | WO2022231978A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| WO2025064944A1 (en) * | 2023-09-20 | 2025-03-27 | Vor Biopharma Inc. | Anti-cd45 antibody-drug conjugate pharmaceutical compositions |
| CN121263444A (zh) * | 2024-03-08 | 2026-01-02 | 孙氏医药有限公司 | 抗半乳糖凝集素3抗体和其在癫痫和相关疾病中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| AU2018263868A1 (en) * | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| AU2020214796A1 (en) * | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) * | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
-
2022
- 2022-04-22 JP JP2023565628A patent/JP2024515968A/ja active Pending
- 2022-04-22 CN CN202280045350.2A patent/CN117561080A/zh active Pending
- 2022-04-22 WO PCT/US2022/026005 patent/WO2022231978A1/en not_active Ceased
- 2022-04-22 EP EP22796456.6A patent/EP4329804A4/en active Pending
-
2023
- 2023-10-23 US US18/492,607 patent/US20240158512A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020244614B2 (en) | Stable protein solution formulation containing high concentration of an anti-VEGF antibody | |
| CN111315411B (zh) | 高浓度抗c5抗体制剂 | |
| AU2005330672B2 (en) | Stabilized anti-hepatitis B (HBV) antibody formulations | |
| JP2022036932A5 (https=) | ||
| WO2013164789A2 (en) | Antibody formulatoin | |
| JP2008528638A5 (https=) | ||
| IL268202B1 (en) | Anti-rsv monoclonal antibody formulation | |
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| CN110732023A (zh) | 一种her2抗体药物组合物及其用途 | |
| JP2019532970A5 (https=) | ||
| WO2005072772A1 (en) | Pharmaceutical compositions | |
| WO2022017468A1 (zh) | Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JPWO2022231978A5 (https=) | ||
| JPWO2020243031A5 (https=) | ||
| TW202124454A (zh) | 抗ｐｃｓｋ９抗體用於預防或治療膽固醇相關疾病的方法 | |
| JPWO2023019171A5 (https=) | ||
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| JPWO2023086817A5 (https=) | ||
| JPWO2022043900A5 (https=) | ||
| KR20240100493A (ko) | 항-cd22 항체의 수성 제제 및 이의 용도 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| JP2024522165A (ja) | ２０１９新型コロナウイルス抗体含有医薬製剤 | |
| RU2025131684A (ru) | Способы лечения множественной миеломы |